psoriasis

stock market down crash fail shares

Ventyx's last hope for inflammatory med ends in Crohn's failure

Ventyx’s Crohn’s drug didn't help patients achieve remission in a phase 2 trial, sending the biotech’s shares down 20% pre-market Monday morning.

Annalee Armstrong Jul 29, 2024 9:45am

Wall Street IPO initial public offering markets shares stock

Alumis downsizes IPO, tacks on private placement

Jun 28, 2024 5:02am

Photo of Wall Street street sign with american flags in the background

Alumis eyes $300M IPO to fund clinical-stage TYK2 pipeline

Jun 24, 2024 8:14am

Graphic image of the letters IPO in white in front of a yellow background

Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials

Jun 10, 2024 8:35am

skin cells epidermis layers lotion serum

Innovent looks to Chinese regulators after ph. 3 psoriasis win

May 28, 2024 7:55am

Podcast

Womens Health The Top Line

'The Top Line': Inclusivity in psoriasis trials with Takeda

Mar 15, 2024 7:00am